Project description:Transcriptional profiling of the melanoma SK-mel-103 comparing control untreated cells with cells treated with 1ug/ml of polyinosine-polycytidylic acid (pIC) or 1ug/ml of pIC with polyethyleneimine (PEI) for 4 or 10 hours. Keywords: Treatment Four-condition experiment, SK-Mel-103 untreated vs. SK-Mel-103 treated with pIC/pIC+PEI at 4 and 10 hours. One replicate per array.
Project description:Transcriptional profiling of the melanoma SK-mel-103 comparing control untreated cells with cells treated with 1ug/ml of polyinosine-polycytidylic acid (pIC) or 1ug/ml of pIC with polyethyleneimine (PEI) for 4 or 10 hours. Keywords: Treatment
Project description:Analysis of transcriptome kinetics of SW1736 thyroid cancer cell line vs SK-MEL-28 melanoma cell line at various times after addition of 2 µM vemurafenib. The hypothesis tested was that SW1736 cells (vemurafenib-refractory) differentially express genes compared to SK-MEL-28 cells (vemurafenib sensitive) that confer resistance to the RAF inhibitor. Total RNA was obtained from lysates of SW1726 and SK-MEL-28 cells treated with 2 µM vemurafenib for 0, 1, 6 and 48 h. Experiment was made by triplicate.
Project description:We have identified CUGBP1 dependent regulation of cell cycle and DNA replication/synthesis networks in melanoma cells. This data set we include gene expression and alternative splicing data of control and CUGBP1 depleted melanoma cell lines (SK-Mel-103 and UACC-62).
Project description:The experiment was designed to profile the transcriptome of human melanoma cell lines that differ in their delta ex2/3p73 expression. The differential gene expression of SK-Mel-29 stably overexpressing delta ex2/3p73-cDNA (SK-Mel-29.DNp73) was analyzed in comparison to parental cells with integrated empty vector . The DNp73-related gene expression signature was compared to the transcriptome of SK-Mel-103 and SK-Mel-147 cells with high endogenous DNp73 expression.
Project description:Analysis of transcriptome kinetics of SW1736 thyroid cancer cell line vs SK-MEL-28 melanoma cell line at various times after addition of 2 µM vemurafenib. The hypothesis tested was that SW1736 cells (vemurafenib-refractory) differentially express genes compared to SK-MEL-28 cells (vemurafenib sensitive) that confer resistance to the RAF inhibitor.
Project description:Analysis of the H3K9me3 and H4K20me3 differential localization over the genome of cancer cells in three conditions: proliferating cells, doxorubicin-treated cells (senescent) and INK128-treated cells (diapause-like). Two cell lines were used to perform the experiment: human melanoma SK-mel-103 cells and human NSCLC A549 cells.
